March 17: The Week in Cancer News
Active monitoring is a viable choice for some with prostate cancer, and more news from the week selected by the editors of Cancer Today.
Progress Against Cancer
Active monitoring is a viable choice for some with prostate cancer, and more news from the week selected by the editors of Cancer Today.
A targeted therapy regimen was approved to treat some children with brain cancer The U.S. Food and Drug Administration (FDA) has approved dabrafenib (Tafinlar) in combination with trametinib (Mekinist) for pediatric patients 1 year...
The 2020 death of actor Chadwick Boseman shocked the public, sparking grief in those who revered his portrayal of the Black Panther. It also raised questions about how a young man who appeared healthy...
The immune system is designed to operate like a well-oiled machine. With a myriad of distinct cell types, a handful of specialized organs, and a network of watchtowers spread throughout the body, the immune...
The FDA sets rule that requires mammography providers to notify women who have dense breasts, and more news selected by the editors of Cancer Today.
The FDA approved abemaciclib with endocrine therapy for HR-positive, HER2-negative, early-stage breast cancer at high risk of recurrence. The U.S. Food and Drug Administration (FDA) has approved abemaciclib (Verzenio) with endocrine therapy (tamoxifen or...
Exercising only 11 minutes per day can reduce your cancer risk, and new robotic technology helps detect early-stage lung cancer.
In the United States, about 40% of cancer cases are associated with preventable risk factors. According to the AACR Cancer Progress Report 2022, 15 types of cancer have been linked to being overweight or...
A study found women in California were more likely to have cervical cancer diagnoses at a later stage after age 65.
Aggressive end-of-life measures are common in people with advanced cancer in nursing homes, and more news selected by the editors of Cancer Today.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More